×
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
NASDAQ:IONS

Ionis Pharmaceuticals Stock Forecast, Price & News

$37.02
-0.54 (-1.44%)
(As of 06/30/2022 04:00 PM ET)
Add
Compare
Today's Range
$36.68
$37.76
50-Day Range
$31.71
$42.34
52-Week Range
$25.04
$44.42
Volume
774,263 shs
Average Volume
1.12 million shs
Market Capitalization
$5.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.44
30 days | 90 days | 365 days | Advanced Chart

Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Stock Forecast (MarketRank)

Overall MarketRank

1.86 out of 5 stars

Medical Sector

733rd out of 1,433 stocks

Pharmaceutical Preparations Industry

350th out of 684 stocks

Analyst Opinion: 2.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Ionis Pharmaceuticals logo

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Stock News Headlines

TheStreet Lowers Ionis Pharmaceuticals (NASDAQ:IONS) to D
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
660
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
6/30/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$43.44
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+17.4%
Consensus Rating
Hold
Rating Score (0-4)
2.125
Research Coverage
8 Analysts

Profitability

Net Income
$-28.60 million
Pretax Margin
-0.41%

Debt

Sales & Book Value

Annual Sales
$810 million
Cash Flow
$0.09 per share
Book Value
$5.47 per share

Miscellaneous

Free Float
138,452,000
Market Cap
$5.25 billion
Optionable
Optionable
Beta
0.78














Ionis Pharmaceuticals Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals
or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price forecast for 2022?

8 analysts have issued twelve-month target prices for Ionis Pharmaceuticals' stock. Their IONS stock forecasts range from $26.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $43.44 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Ionis Pharmaceuticals' stock price performed in 2022?

Ionis Pharmaceuticals' stock was trading at $30.43 at the beginning of the year. Since then, IONS stock has increased by 21.7% and is now trading at $37.02.
View the best growth stocks for 2022 here
.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Ionis Pharmaceuticals
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.22. The firm had revenue of $142 million for the quarter, compared to analyst estimates of $122.46 million. Ionis Pharmaceuticals had a negative net margin of 0.36% and a negative trailing twelve-month return on equity of 0.46%. Ionis Pharmaceuticals's quarterly revenue was up 26.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.64) earnings per share.
View Ionis Pharmaceuticals' earnings history
.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $612.37 million.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:
  • Dr. Brett P. Monia Ph.D., Founder, CEO & Director (Age 61, Pay $1.32M)
  • Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 60, Pay $869.38k) (LinkedIn Profile)
  • Ms. Onaiza Cadoret-Manier, Exec. VP and Chief Product Strategy & Operations Officer (Age 57, Pay $755.52k)
  • Mr. Patrick R. O'Neil Esq., Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 48, Pay $815.69k)
  • Dr. Stanley T. Crooke, Scientific Advisor (Age 77, Pay $1.64M)
  • Ms. B. Lynne Parshall Esq., J.D., Sr. Strategic Advisor & Director (Age 68, Pay $701.77k) (LinkedIn Profile)
  • Dr. Eric E. Swayze Ph.D., Exec. VP of Research (Age 56, Pay $739.3k)
  • Mr. Joel Edwards, VP of Corp. Operations (Age 61)
  • Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
  • Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 65)

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $37.02.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.25 billion and generates $810 million in revenue each year. The company earns $-28.60 million in net income (profit) each year or ($0.200010) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 660 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for Ionis Pharmaceuticals is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at [email protected], or via fax at 760-603-2700.

This page (NASDAQ:IONS) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.